The Ripple dove into the realities of biotech in food, gathering investors and entrepreneurs to ask some tough questions. The group weighed in on what’s working and what isn’t in scaling up biotech ideas, especially in food production.

Here’s what stood out:

- Getting real revenue is a must for most investors.

- Companies selling dreams without proof just don’t cut it.

- Scaling biotech isn’t like flipping a switch—biology doesn’t double when you double the size.

- Consumer demand is still shaky. Most folks aren’t actively begging for alternative proteins yet.

- Investors are carefully balancing risk with long-term vision. De-risking matters.

- New tech in food means bridging supply gaps, not just creating buzz.

Big takeaway? Bringing biotech to food is tough but optimistic. Success depends on real demand, steady scaling, and honest investor-founder conversations.